EMCURE PHARMACEUTICALS L Share Price

Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.As of 25 May 2026, EMCURE PHARMACEUTICALS L share price is ₹1,740.00. The stock opened at ₹1,713.60, compared to its previous close of ₹1,713.60. During today's trading session, EMCURE PHARMACEUTICALS L share price moved in the range of ₹1,705.00 to ₹1,740.90, with an average price of ₹1,722.95 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,705.00 and a high of ₹1,740.90. On the performance front, EMCURE PHARMACEUTICALS L share price has increased by 26.50% over the last six months and is up 46.75% on a year-on-year basis.

The market capitalization of EMCURE PHARMACEUTICALS L is ₹32,463 Crs, with a P/E ratio of 34.5 and a dividend yield of 0.00%.